STOCK TITAN

Sensus Healthcare Inc - SRTS STOCK NEWS

Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.

Sensus Healthcare, Inc. (Nasdaq: SRTS) is a leading medical device company dedicated to providing non-invasive and cost-effective treatments for non-melanoma skin cancer and keloids. Utilizing a proprietary low-energy x-ray radiation technology known as Superficial Radiation Therapy (SRT), Sensus Healthcare has made significant advancements in the field over more than a decade of dedicated research and development. The company’s flagship products, the SRT-100™ and SRT-100 Vision™, effectively and safely treat a variety of oncological and non-oncological skin conditions, including basal cell and squamous cell skin cancers, as well as keloids.

Based in Boca Raton, Florida, Sensus Healthcare focuses on creating innovative, minimally-invasive solutions that address critical medical needs. The company has recently announced a multi-faceted collaboration with CureRays, a radiation oncology specialist organization headquartered in Atlanta and Grass Valley, California. This partnership aims to enhance the reach and efficacy of Sensus's SRT technology, further solidifying its position as a leader in the non-invasive treatment market.

Sensus Healthcare generates the majority of its revenue from customers within the United States, offering products and services that meet the highest standards of safety and effectiveness. The company’s proprietary technology has been incorporated into its diverse portfolio, which includes the SRT-100™, SRT-100 Vision™, and a comprehensive Sentinel service program that ensures optimal device performance and customer satisfaction.

Investors and stakeholders are encouraged to stay informed about Sensus Healthcare’s latest developments. Recently, the company announced it would hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones. This call will offer an in-depth overview of the company’s financial health and strategic initiatives.

For more detailed information about Sensus Healthcare, its innovative technology, products, and recent news, please visit Sensus Healthcare’s official website.

Rhea-AI Summary

Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a virtual fireside chat with CEO Joseph Sardano and CFO Javier Rampolla on October 19, 2021, at 11:00 a.m. ET. This session, organized by Maxim Group LLC and M-Vest, invites professional investors to register in advance. A 48-hour replay will be available post-event on the company’s investor website. Sensus Healthcare specializes in innovative, non-invasive treatments for oncological and non-oncological conditions, including its Sculptura™ system and SRT-100™ technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences
-
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) has received a five-year license renewal from the Chinese Health Authority to market its SRT-100™ system for treating non-melanoma skin cancer and keloids in Greater China. The new license, effective until December 2026, reflects the company's successful presence with 46 units installed in various medical facilities across China. The CEO expressed optimism about post-pandemic sales recovery and remarked on a new distribution agreement with Ekpac Healthcare. Sensus also anticipates marketing authorization for its Sculptura™ system by late 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) announces participation in the upcoming Fall Clinical Dermatology Conference from October 21-24, 2021, in Las Vegas. Over 1,200 physicians are registered to attend this first major in-person dermatology event in 18 months. Key opinion leaders will present on superficial radiation therapy (SRT) for non-melanoma skin cancer. CEO Joe Sardano emphasizes strong sales momentum for the second half of 2021, driven by favorable reimbursement changes and a backlog of orders. Sensus anticipates achieving profitability this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
none
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS), based in Boca Raton, Fla., will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually from September 13 to 15, 2021. CEO Joe Sardano's presentation will be accessible via a webcast starting at 7:00 am (EST) on September 13. Sensus Healthcare specializes in non-invasive treatments for both oncological and non-oncological conditions, featuring technologies like the Sculptura™ and SRT-100™ systems, aimed at enhancing patient quality of life.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
conferences
-
Rhea-AI Summary

Sensus Healthcare (SRTS) reported Q2 2021 revenues of $5.4 million, a 358% increase year-over-year and 77% sequentially. The net loss narrowed to $(0.3) million or $(0.02) per share, improving from $(2.6) million or $(0.16) per share in Q2 2020. The company shipped 17 systems, enhancing its installed base to 515 systems. Cash stood at $15.2 million with no long-term debt. Management expressed optimism for continued growth, aided by new reimbursement schedules and an expanded international strategy, particularly in China and India.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
-
Rhea-AI Summary

Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on August 5, 2021, at 4:30 p.m. Eastern to discuss its Q2 2021 financial results and provide business updates. The call will be accessible via dial-in numbers and a live webcast. Sensus is focused on non-invasive medical treatments for various conditions, including its Sculptura™ and SRT systems for cancer treatment and skin conditions. This call aims to communicate recent achievements and future milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
conferences earnings
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS), a leader in non-invasive medical devices, announced management's participation in A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021. The conference will facilitate one-on-one virtual meetings with investors. Sensus specializes in innovative treatments for oncological and non-oncological conditions, including the Sculptura™ system for radiation therapy and SRT-100™ for treating skin cancers. The company's focus is on enhancing patient quality of life through advanced technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
none
-
Rhea-AI Summary

Sensus Healthcare reported an 83% revenue increase year-over-year, achieving $3.1 million in the first quarter of 2021 compared to $1.7 million in 2020. The company installed its 500th unit and narrowed its net loss to $1.1 million or $0.07 per share, down from $3.6 million or $0.22 per share last year. Gross profit rose to $1.6 million, with a gross margin of 51.6%. Cash and equivalents totaled $13.7 million as of March 31, 2021. Management anticipates continued revenue growth driven by higher reimbursement rates and expanding market acceptance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
-
Rhea-AI Summary

Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a conference call on May 6, 2021, at 4:30 p.m. Eastern Time to discuss its Q1 2021 financial results and provide a business update. The call will be accessible via dial-in numbers (888-390-3967 for U.S. and Canada; 862-298-0702 for international) and a live webcast. Sensus Healthcare specializes in non-invasive medical devices for oncological and non-oncological conditions, including the Sculptura™ system and SRT-100™ technology for skin cancer treatments, emphasizing innovation in patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) announced a significant milestone as its SRT-100™ system successfully treated its first canine patient, Daisy, at Colorado State University's Flint Animal Cancer Center. Daisy had two mast cell tumors that were reduced after six treatments, avoiding surgery. This landmark event highlights Sensus's innovations in superficial radiation therapy (SRT), expanding the potential use of their technology in veterinary medicine. The partnership aims to develop treatment protocols and publish clinical data, promoting the commercial viability of SRT-100 in a new market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none

FAQ

What is the current stock price of Sensus Healthcare (SRTS)?

The current stock price of Sensus Healthcare (SRTS) is $5.38 as of February 21, 2025.

What is the market cap of Sensus Healthcare (SRTS)?

The market cap of Sensus Healthcare (SRTS) is approximately 91.7M.

What is Sensus Healthcare, Inc.?

Sensus Healthcare, Inc. is a medical device company specializing in non-invasive treatments for non-melanoma skin cancer and keloids, utilizing proprietary Superficial Radiation Therapy (SRT) technology.

What products does Sensus Healthcare offer?

Sensus Healthcare offers the SRT-100™ and SRT-100 Vision™, which are devices designed to treat oncological and non-oncological skin conditions.

What is Superficial Radiation Therapy (SRT)?

Superficial Radiation Therapy (SRT) is a low-energy x-ray radiation technology used by Sensus Healthcare to treat conditions like non-melanoma skin cancer and keloids effectively and safely.

Where is Sensus Healthcare based?

Sensus Healthcare is based in Boca Raton, Florida.

What recent collaborations has Sensus Healthcare announced?

Sensus Healthcare recently announced a collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, California.

How does Sensus Healthcare generate its revenue?

Sensus Healthcare generates the majority of its revenue from customers in the United States through the sale of its medical devices and services.

What is the Sentinel service program?

The Sentinel service program is a comprehensive service offered by Sensus Healthcare to ensure optimal device performance and customer satisfaction.

When is the next conference call for Sensus Healthcare?

Sensus Healthcare will hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones.

Where can I find more information about Sensus Healthcare?

More information about Sensus Healthcare can be found on their official website at www.sensushealthcare.com.

What conditions can Sensus Healthcare’s devices treat?

Sensus Healthcare’s devices can treat oncological skin conditions like basal cell and squamous cell skin cancers, as well as non-oncological conditions such as keloids.
Sensus Healthcare Inc

Nasdaq:SRTS

SRTS Rankings

SRTS Stock Data

91.71M
13.57M
19.01%
24.27%
3.27%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
BOCA RATON